|
Impact of Canagliflozin on Renoprotection in T2DM
|
 Will SGLT2 inhibitor canagliflozin prove renoprotective in T2DM patients? CANVAS study authors sought to find out.
(©crystal light/Shutterstock.com) [mousetype]
|
|
Read more
|
Long-acting rhGH May Reduce Treatment Frequency for AGHD Patients
|
| The novel long-acting recombinant human growth hormone may lower number of growth hormone treatments from daily to 2 times per month.
|
|
Read more
|
